Conclusion: This study shows that new anti-diabetic drugs, particularly GLP1-RA and Tirzepatide, are the most effective in inducing weight loss in patients with type 2 diabetes. Interestingly, exenatide appears to be the only GLP1-RA that induces a mild weight loss.
PubMed 34302978 ↗Semaglutide
Also known as Ozempic, Wegovy, Rybelsus
The short answer. More people than not who report on Semaglutide say it helped (64% of 228). It is most often used for weight loss: 85% of 138 reports say that improved. It is well studied — 421 meta-analyses on PubMed. The most common complaint is nausea.
From 330 mentions in total — the rest didn't say how it went and aren't counted.
What Semaglutide does, according to users
Of the people who reported each effect, the share who said it got better.
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 421 meta-analyses on PubMed ↗ · 307 randomized trials ↗
Conclusion: Among individuals with obesity without type 2 diabetes, subcutaneous semaglutide is effective for weight loss with an 11.85% reduction from baseline compared to placebo. This supports the use of semaglutide for weight management in obesity. However, risk of gastrointestinal adverse events, discontinuation of treatment and serious adverse events were higher in the semaglutide group versus placebo.
PubMed 36578889 ↗Conclusion: Potent GLP-1 RAs, such as tirzepatide and semaglutide, demonstrate greater overall weight loss but are associated with a significant reduction in lean mass.
PubMed 39719170 ↗Conclusion: The proportion of weight regained was proportional to the amount originally lost. Meaning: Discontinuation of GLP-1RA treatment leads to weight regain, regardless of lifestyle interventions, and should therefore be considered a chronic therapy to prevent weight regain and associated undesirable outcomes related to obesity.
PubMed 40186344 ↗778 human trials on ClinicalTrials.gov test Semaglutide — 350 completed, 167 recruiting now. See all on ClinicalTrials.gov ↗
- Semaglutide in Women With Polycystic Ovary Syndrome and Obesity · Polycystic Ovary Syndrome (PCOS) Women, Obesity · 2026
- Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance · Obesity and Obesity-related Medical Conditions, Obesity and Overweight · 2026
- Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets · Overweight, Obesity · 2026
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
Boxed warning (the FDA's strongest label warning): “RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human…”
48 recalls of products named for Semaglutide. Most recent:
- 2026-08-19 · Class II: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material record ↗
- 2026-04-22 · Class II: Lack of Assurance of Sterility record ↗
- 2026-03-11 · Class II: CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution record ↗
Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗
LiverTox rates Semaglutide D — a possible rare cause of liver injury (1–3 published cases). LiverTox entry ↗
NIH has funded 21 research projects with Semaglutide in the title, $18,663,689 in total (2021–2026). NIH RePORTER ↗
Plain-language guides from the US government: MedlinePlus: Semaglutide ↗
Dosage people report
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“I've lost 35lbs since then and now I'm in the Healthy range on BMI. My IBSD has virtually disappeared.”
“I tried ozempic at first. Made me really sick so I stopped.”
“Other things I take are semiglutide and TRT... recently made some major life changes and lost 80 pounds.”
“I recently cycled off Ozempic after 6 months. It did not agree with me...profund depression...profound depression(something I dont normally have an issue with).”
Top discussions (5)
- Ozempic Is Changing People’s Skin, Say Plastic Surgeons "Dr. Few started to notice a trend: The skin quality of someone on a GLP-1 was reminding him of an “old, overused rubber band.”' ↗
- Ozempic will disrupt big tobacco, candy companies, and alcohol brands, according to Morgan Stanley ↗
- Poopmaxxing ↗
- Before and afters, 1 year on maintenance with Semaglutide ↗
- Reta weight loss progress ↗
Semaglutide compared
Other options for weight loss
Sources
- User reports: 330 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- FDA drug label (DailyMed) ↗
- FDA recalls ↗
- LiverTox (NIH) ↗
- MedlinePlus (NIH) ↗
- NIH RePORTER ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate